Results 91 to 100 of about 171,176 (147)

0860 Subjective Sleep Quality with Low-Sodium Oxybate Treatment in Narcolepsy: Results from the DUET Study

SLEEP
Abstract Introduction Jazz DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) is a phase 4, prospective, multicenter, single-arm, multiple-cohort, open-label study (NCT05875974) evaluating the effectiveness of low-sodium oxybate (LXB, Xywav®) treatment on outcomes ...
R Sangal, Emmanuel Mignot, Chad Ruoff, Deborah Nichols, Teresa Steininger, Douglas Fuller, M Kirby, Marisa Whalen, Logan Schneider   +8 more
openaire   +2 more sources

0858 Real-World Experience and Satisfaction with Low-Sodium Oxybate in Narcolepsy: Interim Results from LYRICAL

SLEEP
Abstract Introduction Low-sodium oxybate (LXB; Xywav®) is approved by the US Food and Drug Administration to treat excessive daytime sleepiness (EDS) or cataplexy in patients ≥7 years of age with narcolepsy and adults with idiopathic hypersomnia.
Caroleen Drachenberg, Jennifer Cline, Jennifer D’Souza, Christina Graham, Emily Kim, Meaghan Lawrence, Meagan Farrell, Grecia Sanchez, Donald Stull, Marisa Whalen, Jessica Alexander, Laura Herpel   +11 more
openaire   +2 more sources

0633 Efficacy and Safety of Low-Sodium Oxybate in Narcolepsy Patients With/Without Psychiatric/Neurologic Comorbidities

SLEEP
Abstract Introduction Prior studies report high incidences of psychiatric and/or neurologic comorbidities in patients with narcolepsy. Low-sodium oxybate (LXB; Xywav®) is an FDA-approved treatment for cataplexy or excessive daytime sleepiness in patients ≥7 years old with narcolepsy and for adults ...
Craig Chepke, Andrew Cutler, Nathaniel Watson, Shawn Candler, Douglas Fuller, Thomas Measey, Brian Scheckner, Sarah Akerman, Wayne Macfadden   +8 more
openaire   +2 more sources

0852 Subjective Sleep Quality with Low-Sodium Oxybate Treatment in Idiopathic Hypersomnia: Results from the DUET Study

SLEEP
Abstract Introduction Jazz DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) is a phase 4, prospective, multicenter, single-arm, multiple-cohort, open-label study (NCT05875974) evaluating the effectiveness of low-sodium oxybate (LXB, Xywav®) treatment on outcomes ...
Richard Bogan, David Plante, Alyssa Cairns, Deborah Nichols, Teresa Steininger, Douglas Fuller, Sarah Akerman, Marisa Whalen, Nancy Foldvary-Schaefer   +8 more
openaire   +2 more sources

Abstract FR498: Impact of Switching From High- to Low-Sodium Oxybate on Ambulatory and Office Blood Pressure in Subgroups of People With Narcolepsy From the XYLO Study

Hypertension
Introduction: Excess sodium intake is strongly linked with hypertension and cardiovascular disease (CVD); people with narcolepsy (PwN) have increased CV risk. Hypothesis: Switching from high-sodium oxybate (SXB; Xyrem
Virend Somers, Richard Kovacs, Jessica Alexander, Christine Baranak, Deborah Nichols, Jing Dai, Marisa Whalen, Akinyemi Ajayi, barbara hutchinson, Yves Dauvilliers, William White   +10 more
openaire   +2 more sources

0639 Long-term Safety and Timing of Adverse Events with Low-Sodium Oxybate in a Phase 3 Idiopathic Hypersomnia Study

SLEEP
Abstract Introduction Low-sodium oxybate (LXB; Xywav®) is approved by the US Food and Drug Administration for the treatment of idiopathic hypersomnia in adults. To examine the long-term safety of LXB in this population, this post hoc analysis evaluated treatment-emergent adverse events (TEAEs) over ...
Richard Bogan, Marisa Whalen, Stefanie Bronson, Douglas Fuller, Wayne Macfadden   +4 more
openaire   +2 more sources

0632 Design Elements for a Switch Study from High- to Low-Sodium Oxybate Evaluating Blood Pressure in Narcolepsy (XYLO)

SLEEP
Abstract Introduction High sodium intake can increase blood pressure (BP) and future cardiovascular risk. Individuals with narcolepsy have an elevated cardiovascular comorbidity burden before considering medication-specific risks.
William White, Wayne Macfadden, Christine Baranak, Deborah Nichols, Sarah Akerman, Virend Somers   +5 more
openaire   +2 more sources

Efficacy and Safety of Low-Sodium Oxybate in Narcolepsy Patients With/Without Psychiatric/Neurologic Comorbidities (P12-2.004)

Neurology
Craig Chepke, Andrew Cutler, Nathaniel Watson, Shawn Candler, Douglas Fuller, Thomas Measey, Brian Scheckner, Sarah Akerman   +7 more
openaire   +2 more sources

Insights from real-world and interventional studies of patients transitioning from sodium oxybate to low-sodium oxybate

Sleep Medicine
W. Macfadden, A.M. Husain, P.C. Zee, D.S. Fuller, S. Candler, C. Bae   +5 more
openaire   +2 more sources

Blood pressure changes after treatment with low-sodium oxybate in oxybate-naive patients with narcolepsy or idiopathic hypersomnia: a post hoc analysis

Sleep Medicine
W. Macfadden, S. Candler, D.S. Fuller, T.J. Measey, W.B. White   +4 more
openaire   +2 more sources